274 related articles for article (PubMed ID: 29381221)
1. Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis.
Stathopoulos P; Kumar A; Heiden JAV; Pascual-Goñi E; Nowak RJ; O'Connor KC
Ann N Y Acad Sci; 2018 Jan; 1412(1):154-165. PubMed ID: 29381221
[TBL] [Abstract][Full Text] [Related]
2. Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis.
Stathopoulos P; Kumar A; Nowak RJ; O'Connor KC
JCI Insight; 2017 Sep; 2(17):. PubMed ID: 28878127
[TBL] [Abstract][Full Text] [Related]
3. Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing.
Vander Heiden JA; Stathopoulos P; Zhou JQ; Chen L; Gilbert TJ; Bolen CR; Barohn RJ; Dimachkie MM; Ciafaloni E; Broering TJ; Vigneault F; Nowak RJ; Kleinstein SH; O'Connor KC
J Immunol; 2017 Feb; 198(4):1460-1473. PubMed ID: 28087666
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology.
Fichtner ML; Jiang R; Bourke A; Nowak RJ; O'Connor KC
Front Immunol; 2020; 11():776. PubMed ID: 32547535
[TBL] [Abstract][Full Text] [Related]
5. Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy.
Fichtner ML; Hoehn KB; Ford EE; Mane-Damas M; Oh S; Waters P; Payne AS; Smith ML; Watson CT; Losen M; Martinez-Martinez P; Nowak RJ; Kleinstein SH; O'Connor KC
Acta Neuropathol Commun; 2022 Oct; 10(1):154. PubMed ID: 36307868
[TBL] [Abstract][Full Text] [Related]
6. Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients.
Takata K; Stathopoulos P; Cao M; Mané-Damas M; Fichtner ML; Benotti ES; Jacobson L; Waters P; Irani SR; Martinez-Martinez P; Beeson D; Losen M; Vincent A; Nowak RJ; O'Connor KC
JCI Insight; 2019 Jun; 4(12):. PubMed ID: 31217355
[TBL] [Abstract][Full Text] [Related]
7. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis.
Marino M; Basile U; Spagni G; Napodano C; Iorio R; Gulli F; Todi L; Provenzano C; Bartoccioni E; Evoli A
Front Immunol; 2020; 11():613. PubMed ID: 32431692
[TBL] [Abstract][Full Text] [Related]
8. Short- and Long-Lived Autoantibody-Secreting Cells in Autoimmune Neurological Disorders.
Zografou C; Vakrakou AG; Stathopoulos P
Front Immunol; 2021; 12():686466. PubMed ID: 34220839
[TBL] [Abstract][Full Text] [Related]
9. Longstanding and Refractory Anti-Muscle Specific Tyrosine Kinase Antibody-Associated Myasthenia Gravis (Anti-MuSK-MG) in a Child Successfully Treated with Rituximab.
Weger S; Appendino JP; Clark IH
J Binocul Vis Ocul Motil; 2019; 69(1):26-29. PubMed ID: 30811277
[TBL] [Abstract][Full Text] [Related]
10. Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia gravis relapses.
Jiang R; Fichtner ML; Hoehn KB; Pham MC; Stathopoulos P; Nowak RJ; Kleinstein SH; O'Connor KC
JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32573488
[TBL] [Abstract][Full Text] [Related]
11. Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis.
Hurst RL; Gooch CL
Curr Neurol Neurosci Rep; 2016 Jul; 16(7):61. PubMed ID: 27170368
[TBL] [Abstract][Full Text] [Related]
12. Myasthenia gravis with antibodies to MuSK: an update.
Evoli A; Alboini PE; Damato V; Iorio R; Provenzano C; Bartoccioni E; Marino M
Ann N Y Acad Sci; 2018 Jan; 1412(1):82-89. PubMed ID: 29266255
[TBL] [Abstract][Full Text] [Related]
13. Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody.
Zhou Y; Yan C; Gu X; Zhou L; Lu J; Zhu W; Huan X; Luo S; Zhong H; Lin J; Lu J; Zhao C; Xi J
Muscle Nerve; 2021 Jun; 63(6):824-830. PubMed ID: 33745138
[TBL] [Abstract][Full Text] [Related]
14. Autoimmune myasthenia gravis: autoantibody mechanisms and new developments on immune regulation.
Le Panse R; Berrih-Aknin S
Curr Opin Neurol; 2013 Oct; 26(5):569-76. PubMed ID: 23995274
[TBL] [Abstract][Full Text] [Related]
15. Relation of HLA-DRB1 to IgG4 autoantibody and cytokine production in muscle-specific tyrosine kinase myasthenia gravis (MuSK-MG).
Çebi M; Durmuş H; Yılmaz V; Yentür SP; Aysal F; Oflazer P; Parman Y; Deymeer F; Saruhan-Direskeneli G
Clin Exp Immunol; 2019 Aug; 197(2):214-221. PubMed ID: 30929252
[TBL] [Abstract][Full Text] [Related]
16. Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis.
Plomp JJ; Huijbers MG; van der Maarel SM; Verschuuren JJ
Ann N Y Acad Sci; 2012 Dec; 1275():114-22. PubMed ID: 23278586
[TBL] [Abstract][Full Text] [Related]
17. Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics.
Lazaridis K; Tzartos SJ
Front Immunol; 2020; 11():212. PubMed ID: 32117321
[TBL] [Abstract][Full Text] [Related]
18. IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients.
Koneczny I; Stevens JA; De Rosa A; Huda S; Huijbers MG; Saxena A; Maestri M; Lazaridis K; Zisimopoulou P; Tzartos S; Verschuuren J; van der Maarel SM; van Damme P; De Baets MH; Molenaar PC; Vincent A; Ricciardi R; Martinez-Martinez P; Losen M
J Autoimmun; 2017 Feb; 77():104-115. PubMed ID: 27965060
[TBL] [Abstract][Full Text] [Related]
19. Anti-MuSK myasthenia gravis presenting with purely ocular findings.
Caress JB; Hunt CH; Batish SD
Arch Neurol; 2005 Jun; 62(6):1002-3. PubMed ID: 15956173
[TBL] [Abstract][Full Text] [Related]
20. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.
Vincent A; Leite MI
Curr Opin Neurol; 2005 Oct; 18(5):519-25. PubMed ID: 16155434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
